UK myocardial infarction (MI) market is estimated to grow considerably at a CAGR of around 7.2% during the forecast period. UK has one of the finest healthcare systems in the EU region which enables it to provide quality healthcare to the individual citizens. UK has the highest number of CVD, CHD, MI, stroke, heart failure, atrial fibrillation, and other heart patients. According to the British Heart Foundation, more than one- a fourth of the fatalities in UK are due to CVD, which is responsible for around 1.6 million fatalities each year. The critical factors that are leading to CVD, CHD, MI, stroke, and other heart diseases include work-related stress, depression, excessive consumption of alcohol, excessive smoking, hypertension, diabetes, obesity, and poor diet which includes cholesterol.
To learn more about this report request a sample copy @ https://www.omrglobal.com/request-sample/uk-myocardial-infarction-market
The market is segmented into type, device, diagnosis, treatment, and end-user. Based on type, the market is segmented into ST-elevation myocardial infarction (STEMI) heart attacks, non-ST elevation myocardial infarction (NSTEMI) heart attacks, and silent heart attacks. Based on the device, the market is segmented into left ventricular assist device, pacemaker, implantable cardioverter defibrillator, and others (aspiration-based catheters). Based on the diagnosis, the market is segmented into an electrocardiography (ECG), chest X-Ray, Computed Tomography (CT Scan), echocardiography, and others (blood test). Based on treatment, the market is segmented into medication and surgery. Based on end-user, the market is segmented into hospitals & clinics, Ambulatory Surgical Centers (ASCs), and research institutes.
The companies which are contributing to the growth of the UK myocardial infarction market include AstraZeneca PLC, Bayer AG, Boehringer Ingelheim International GmbH, Novartis AG, GlaxoSmithKline PLC, Koninklijke Philips N.V., Medtronic PLC, and Merck KGaA. The market players are considerably contributing to the market growth by the adoption of various strategies including new product launch, merger, and acquisition, collaborations with government, funding to the start-ups, and technological advancements to stay competitive in the market. For instance, in October 2019, AstraZeneca PLC’s Farxiga was approved in the US. The drug aids in reducing the risk of hospitalization for heart failure in patients with type-2 diabetes. Thus, through this approval, the company seeks to extend its product portfolio and serve a large customer base across the globe.
UK Myocardial Infarction Market Segmentation
By Type
- Non-ST-elevation myocardial infarction (NSTEMI)
- ST-elevation myocardial infarction (STEMI)
- Silent Heart Attacks
By Device
- Left Ventricular Assist Device (LVAD)
- Pacemaker
- Catheters
- Implantable Cardioverter-Defibrillator (ICD)
- Others (Stent Graft)
By Diagnosis
- Electrocardiography (ECG)
- Chest X-Ray
- Computed Tomography (CT Scan)
- Echocardiography
- Others (Blood Test)
By Treatment
- Medication
- Analgesics
- Thrombolytic
- Antiplatelet Agents
- Glycoprotein IIb/IIIa Inhibitors
- Others (Beta-Adrenergic Blockers)
- Surgery
- Angioplasty
- Bypass Surgery
- Heart Transplant
By End-User
- Hospital & Clinics
- Ambulatory Surgical Centers
- Research Institutes
A full report of UK Myocardial Infarction Market available @ https://www.omrglobal.com/industry-reports/uk-myocardial-infarction-market
Company Profiles
- Abbott Laboratories Inc.
- AstraZeneca PLC
- Bayer AG
- Boehringer Ingelheim International GmbH
- Boston Scientific Corp.
- Bristol-Myers Squibb Co.
- Eli Lilly and Co.
- GlaxoSmithKline Plc
- Johnson & Johnson Services, Inc.
- Koninklijke Philips N.V.
- Medtronic PLC
- Merck KGaA
- Novartis AG
- Pfizer Inc.
- Portola Pharmaceutical Inc.
- Sanofi SA
- Siemens AG
